We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




US Laboratories Surveyed for Malaria Diagnosis

By LabMedica International staff writers
Posted on 06 Jan 2011
The accuracy of laboratories in detecting and identifying malaria parasites and assessing malaria screening practices has been evaluated.

The American Proficiency Institute (API; Traverse City, MI, USA) has examined the diagnostic precision of laboratories in the US to identify different species of malaria parasites and assessed whether the correct follow-up procedures were practiced. More...


Malaria is usually diagnosed in the laboratory by microscopic examination of a stained thick and thin blood smear or by the use of a rapid diagnostic test (RDT). Malaria RDTs detect specific antigens (proteins) produced by malaria parasites, that are present in the blood of infected or recently infected individuals. Some RDTs can detect only one species of the malaria parasite, Plasmodium falciparum, while some also detect other species of the parasite, P. vivax, P. malariae and P. ovale. Blood for these tests are commonly obtained from a finger-prick.

API reviewed proficiency-testing data from 1999 to 2008 to determine the rates of unacceptable responses for detecting and identifying Plasmodium species, the parasites that cause malaria. Laboratories in the United States were better able to detect and identify P. falciparum than other types of parasite species. However, when assessing malaria screening practices among current proficiency testing providers, the review found that half of the surveyed laboratories failed to offer a complete diagnostic workup, 25.0% failed to screen both thick and thin slides, and 36.1% failed to issue a final report within 24 hours.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimates that approximately 1,500 cases of imported malaria are diagnosed each year in the US. Of these, 71% were acquired in Africa and about 41% were due to P. falciparum. In December 2010, an autochthonous case of P. falciparum malaria was diagnosed in a 31-year-old female resident of Jacksonville (FL, USA) who had no history of international travel.

Daniel C. Edson, M.S., M.T. (ASCP), API president and lead author of the report, said, "Malaria is a serious, sometimes fatal, disease and laboratories should be better prepared to identify various species of malaria parasites, the more rapidly patients may be treated and hopefully cured". The study was published in December 2010, in Lab Medicine.

Related Links:

American Proficiency Institute
CDC




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.